We have previously demonstrated that quantification of the antiapoptotic protein BCL2 in patients undergoing neoadjuvant chemotherapy plus radiotherapy for advanced bladder cancer may identify patients who might benefit from neoadjuvant chemotherapy (Cooke et al, 2000). This evidence concerns the gene BCL2 and urinary bladder carcinoma.